Trial Profile
A randomized, double-blind, placebo-controlled phase 3 multicenter study of immediate postoperative instillation of gemcitabine in patients with superficial transitional cell carcinoma of the bladder.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2013
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 03 Nov 2009 Actual number of patients changed from 328 to 355.
- 03 Nov 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Sep 2009 Results published in European Urology.